Total Payments
$247,782
2024 Payments
$154,837
Companies
7
Transactions
44
Payment Breakdown by Category
Research$241,835 (97.6%)
Consulting$4,500 (1.8%)
Travel$1,074 (0.4%)
Food & Beverage$373.51 (0.2%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Unspecified | $241,835 | 34 | 97.6% |
| Consulting Fee | $4,500 | 1 | 1.8% |
| Travel and Lodging | $1,074 | 1 | 0.4% |
| Food and Beverage | $373.51 | 8 | 0.2% |
Payments by Type
Research
$241,835
34 transactions
General
$5,947
10 transactions
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Neurocrine Biosciences, Inc. | $239,499 | 35 | $0 (2024) |
| EMD Serono Research & Development Institute, Inc. | $7,000 | 3 | $0 (2024) |
| PFIZER INC. | $1,074 | 1 | $0 (2019) |
| Eton Pharmaceuticals, Inc. | $83.25 | 1 | $0 (2023) |
| Boston Scientific Corporation | $54.05 | 1 | $0 (2023) |
| Abbott Laboratories | $53.73 | 2 | $0 (2024) |
| Novo Nordisk Inc | $18.12 | 1 | $0 (2023) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $154,837 | 23 | Neurocrine Biosciences, Inc. ($152,284) |
| 2023 | $91,833 | 19 | Neurocrine Biosciences, Inc. ($87,178) |
| 2021 | $37.61 | 1 | Neurocrine Biosciences, Inc. ($37.61) |
| 2019 | $1,074 | 1 | PFIZER INC. ($1,074) |
All Payment Transactions
44 individual payment records from CMS Open Payments — Page 1 of 2
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 11/19/2024 | Neurocrine BioSciences Inc. | — | — | Cash or cash equivalent | $8,483.65 | Research |
| Study: A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO EVALUATE THE SAFETY AND EFFICACY OF CRINECERFONT (NBI-74788) IN ADULT SUBJECTS WITH CLASSIC CONGENITAL ADRENAL HYPERPLASIA, FOLLOWED BY OPEN-LABEL TREATMENT | ||||||
| 11/19/2024 | Neurocrine BioSciences Inc. | — | — | Cash or cash equivalent | $6,302.19 | Research |
| Study: A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO EVALUATE THE SAFETY AND EFFICACY OF CRINECERFONT (NBI-74788) IN ADULT SUBJECTS WITH CLASSIC CONGENITAL ADRENAL HYPERPLASIA, FOLLOWED BY OPEN-LABEL TREATMENT | ||||||
| 10/28/2024 | EMD Serono Research & Development Institute, Inc. | — | — | Cash or cash equivalent | $1,500.00 | Research |
| Study: A Phase II, Randomized, Double-Blind, Placebo-Controlled Dose-Ranging Study To Evaluate the Efficacy and Safety of Enpatoran in Systemic Lupus Erythematosus and in Cutaneous Lupus Erythematosus Participants Receiving Standard of Care | ||||||
| 10/28/2024 | EMD Serono Research & Development Institute, Inc. | — | — | Cash or cash equivalent | $1,000.00 | Research |
| Study: A Phase IIa, Randomized, Double-Blind, Placebo Controlled Study to Evaluate the Efficacy and Safety of Enpatoran in Dermatomyositis and Polymyositis Participants receiving Standard of Care | ||||||
| 10/07/2024 | Neurocrine BioSciences Inc. | — | — | Cash or cash equivalent | $3,263.17 | Research |
| Study: A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO EVALUATE THE SAFETY AND EFFICACY OF CRINECERFONT (NBI-74788) IN ADULT SUBJECTS WITH CLASSIC CONGENITAL ADRENAL HYPERPLASIA, FOLLOWED BY OPEN-LABEL TREATMENT | ||||||
| 09/16/2024 | Neurocrine BioSciences Inc. | — | — | Cash or cash equivalent | $8,513.22 | Research |
| Study: A Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety and Efficacy of Crinecerfont (NBI-74788) in Pediatric Subjects With Classic Congenital Adrenal Hyperplasia, Followed by Open-Label Treatment | ||||||
| 09/16/2024 | Neurocrine BioSciences Inc. | — | — | Cash or cash equivalent | $8,233.23 | Research |
| Study: A Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety and Efficacy of Crinecerfont (NBI-74788) in Pediatric Subjects With Classic Congenital Adrenal Hyperplasia, Followed by Open-Label Treatment | ||||||
| 08/19/2024 | Neurocrine BioSciences Inc. | — | — | Cash or cash equivalent | $3,263.17 | Research |
| Study: A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO EVALUATE THE SAFETY AND EFFICACY OF CRINECERFONT (NBI-74788) IN ADULT SUBJECTS WITH CLASSIC CONGENITAL ADRENAL HYPERPLASIA, FOLLOWED BY OPEN-LABEL TREATMENT | ||||||
| 08/19/2024 | Neurocrine BioSciences Inc. | — | — | Cash or cash equivalent | $2,298.24 | Research |
| Study: A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO EVALUATE THE SAFETY AND EFFICACY OF CRINECERFONT (NBI-74788) IN ADULT SUBJECTS WITH CLASSIC CONGENITAL ADRENAL HYPERPLASIA, FOLLOWED BY OPEN-LABEL TREATMENT | ||||||
| 07/09/2024 | Neurocrine BioSciences Inc. | — | — | Cash or cash equivalent | $4,287.19 | Research |
| Study: A Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety and Efficacy of Crinecerfont (NBI-74788) in Pediatric Subjects With Classic Congenital Adrenal Hyperplasia, Followed by Open-Label Treatment | ||||||
| 07/01/2024 | Neurocrine BioSciences Inc. | — | — | Cash or cash equivalent | $3,263.17 | Research |
| Study: A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO EVALUATE THE SAFETY AND EFFICACY OF CRINECERFONT (NBI-74788) IN ADULT SUBJECTS WITH CLASSIC CONGENITAL ADRENAL HYPERPLASIA, FOLLOWED BY OPEN-LABEL TREATMENT | ||||||
| 06/10/2024 | Neurocrine BioSciences Inc. | — | — | Cash or cash equivalent | $23,340.09 | Research |
| Study: A Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety and Efficacy of Crinecerfont (NBI-74788) in Pediatric Subjects With Classic Congenital Adrenal Hyperplasia, Followed by Open-Label Treatment | ||||||
| 06/10/2024 | Neurocrine BioSciences Inc. | — | — | Cash or cash equivalent | $6,549.79 | Research |
| Study: A Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety and Efficacy of Crinecerfont (NBI-74788) in Pediatric Subjects With Classic Congenital Adrenal Hyperplasia, Followed by Open-Label Treatment | ||||||
| 05/20/2024 | Neurocrine BioSciences Inc. | — | — | Cash or cash equivalent | $8,573.97 | Research |
| Study: A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO EVALUATE THE SAFETY AND EFFICACY OF CRINECERFONT (NBI-74788) IN ADULT SUBJECTS WITH CLASSIC CONGENITAL ADRENAL HYPERPLASIA, FOLLOWED BY OPEN-LABEL TREATMENT | ||||||
| 05/20/2024 | Neurocrine BioSciences Inc. | — | — | Cash or cash equivalent | $2,298.24 | Research |
| Study: A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO EVALUATE THE SAFETY AND EFFICACY OF CRINECERFONT (NBI-74788) IN ADULT SUBJECTS WITH CLASSIC CONGENITAL ADRENAL HYPERPLASIA, FOLLOWED BY OPEN-LABEL TREATMENT | ||||||
| 05/03/2024 | Neurocrine Biosciences, Inc. | — | Food and Beverage | In-kind items and services | $74.07 | General |
| 04/22/2024 | Neurocrine BioSciences Inc. | — | — | Cash or cash equivalent | $7,956.25 | Research |
| Study: A Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety and Efficacy of Crinecerfont (NBI-74788) in Pediatric Subjects With Classic Congenital Adrenal Hyperplasia, Followed by Open-Label Treatment | ||||||
| 03/22/2024 | Neurocrine BioSciences Inc. | — | — | Cash or cash equivalent | $8,224.68 | Research |
| Study: A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO EVALUATE THE SAFETY AND EFFICACY OF CRINECERFONT (NBI-74788) IN ADULT SUBJECTS WITH CLASSIC CONGENITAL ADRENAL HYPERPLASIA, FOLLOWED BY OPEN-LABEL TREATMENT | ||||||
| 03/19/2024 | Neurocrine BioSciences Inc. | — | — | Cash or cash equivalent | $7,162.57 | Research |
| Study: A Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety and Efficacy of Crinecerfont (NBI-74788) in Pediatric Subjects With Classic Congenital Adrenal Hyperplasia, Followed by Open-Label Treatment | ||||||
| 02/03/2024 | Abbott Laboratories | PROCLAIM (Device) | Food and Beverage | In-kind items and services | $37.81 | General |
| Category: Neuromodulation | ||||||
| 02/03/2024 | Abbott Laboratories | PROCLAIM (Device) | Food and Beverage | In-kind items and services | $15.92 | General |
| Category: Neuromodulation | ||||||
| 01/23/2024 | Neurocrine BioSciences Inc. | — | — | Cash or cash equivalent | $22,250.64 | Research |
| Study: A Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety and Efficacy of Crinecerfont (NBI-74788) in Pediatric Subjects With Classic Congenital Adrenal Hyperplasia, Followed by Open-Label Treatment | ||||||
| 01/22/2024 | Neurocrine BioSciences Inc. | — | — | Cash or cash equivalent | $17,946.06 | Research |
| Study: A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO EVALUATE THE SAFETY AND EFFICACY OF CRINECERFONT (NBI-74788) IN ADULT SUBJECTS WITH CLASSIC CONGENITAL ADRENAL HYPERPLASIA, FOLLOWED BY OPEN-LABEL TREATMENT | ||||||
| 12/12/2023 | Neurocrine BioSciences, Inc. | — | — | Cash or cash equivalent | $5,352.50 | Research |
| Study: A Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety and Efficacy of Crinecerfont (NBI-74788) in Pediatric Subjects With Classic Congenital Adrenal Hyperplasia, Followed by Open-Label Treatment | ||||||
| 12/05/2023 | Neurocrine Biosciences, Inc. | — | Food and Beverage | In-kind items and services | $52.68 | General |
Research Studies & Clinical Trials
| Study Name | Company | Amount | Records |
|---|---|---|---|
| A Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety and Efficacy of Crinecerfont (NBI-74788) in Pediatric Subjects With Classic Congenital Adrenal Hyperplasia, Followed by Open-Label Treatment | Neurocrine BioSciences Inc. | $88,293 | 8 |
| A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO EVALUATE THE SAFETY AND EFFICACY OF CRINECERFONT (NBI-74788) IN ADULT SUBJECTS WITH CLASSIC CONGENITAL ADRENAL HYPERPLASIA, FOLLOWED BY OPEN-LABEL TREATMENT | Neurocrine BioSciences Inc. | $63,917 | 10 |
| A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO EVALUATE THE SAFETY AND EFFICACY OF CRINECERFONT (NBI-74788) IN ADULT SUBJECTS WITH CLASSIC CONGENITAL ADRENAL HYPERPLASIA, FOLLOWED BY OPEN-LABEL TREATMENT | Neurocrine BioSciences, Inc. | $43,739 | 8 |
| A Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety and Efficacy of Crinecerfont (NBI-74788) in Pediatric Subjects With Classic Congenital Adrenal Hyperplasia, Followed by Open-Label Treatment | Neurocrine BioSciences, Inc. | $43,387 | 6 |
| A Phase II, Randomized, Double-Blind, Placebo-Controlled Dose-Ranging Study To Evaluate the Efficacy and Safety of Enpatoran in Systemic Lupus Erythematosus and in Cutaneous Lupus Erythematosus Participants Receiving Standard of Care | EMD Serono Research & Development Institute, Inc. | $1,500 | 1 |
| A Phase IIa, Randomized, Double-Blind, Placebo Controlled Study to Evaluate the Efficacy and Safety of Enpatoran in Dermatomyositis and Polymyositis Participants receiving Standard of Care | EMD Serono Research & Development Institute, Inc. | $1,000 | 1 |
About Mimi Kim
Mimi Kim is a Developmental - Behavioral Pediatrics healthcare provider based in Los Angeles, California. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 04/23/2007. The National Provider Identifier (NPI) number assigned to this provider is 1629296181.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Mimi Kim has received a total of $247,782 in payments from pharmaceutical and medical device companies, with $154,837 received in 2024. These payments were reported across 44 transactions from 7 companies. The most common payment nature is "" ($241,835).
Ad
Practice Information
- Specialty Developmental - Behavioral Pediatrics
- Location Los Angeles, CA
- Active Since 04/23/2007
- Last Updated 09/03/2013
- Taxonomy Code 2080P0006X
- Entity Type Individual
- Practice Solo Practitioner
- NPI Number 1629296181
Products in Payments
- ALKINDI (Drug) $83.25
- PROCLAIM (Device) $53.73
- Sogroya (Biological) $18.12
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Developmental - Behavioral Pediatrics Doctors in Los Angeles
Anshu Batra, M.d, M.D
Developmental - Behavioral Pediatrics — Payments: $2,607
Developmental - Behavioral Pediatrics $2,607
Audrey Griesbach, M.d, M.D
Developmental - Behavioral Pediatrics — Payments: $1,663
Developmental - Behavioral Pediatrics $1,663
Gregory Kennedy, Md, MD
Developmental - Behavioral Pediatrics — Payments: $516.27
Developmental - Behavioral Pediatrics $516.27
David Schonfeld, M.d, M.D
Developmental - Behavioral Pediatrics — Payments: $264.97
Developmental - Behavioral Pediatrics $264.97
Gregory Smookler, Md, MD
Developmental - Behavioral Pediatrics — Payments: $64.75
Developmental - Behavioral Pediatrics $64.75
Dr. Douglas Vanderbilt, Md, MD
Developmental - Behavioral Pediatrics
Developmental - Behavioral Pediatrics